On, April 2nd, President Donald Trump issued a proclamation adjusting U.S. imports of pharmaceuticals and pharmaceutical ingredients under Section 232 of the Trade Expansion Act, arguing that heavy reliance on foreign drug manufacturing poses a national security threat. The action follows a Commerce Department investigation concluding that current import levels could impair the United States’ ability to access critical medicines during global supply disruptions or national emergencies.  

The proclamation highlights that approximately 53% of patented pharmaceuticals sold domestically are produced outside the United States, while only 15% of patented active pharmaceutical ingredients (APIs) are manufactured domestically. Administration officials argue this dependence undermines both civilian health systems and military preparedness, particularly for treatments relating to cancer, infectious diseases, and rare conditions.  

To address these concerns, the proclamation imposes a 100% tariff on imported patented pharmaceuticals and related ingredients, effective July 31, 2026. Companies that commit to onshoring production may initially face a lower tariff rate, while firms entering agreements covering domestic manufacturing and “most‑favored‑nation” pricing could qualify for temporary zero‑tariff treatment. The policy also incorporates pharmaceutical commitments in existing trade agreements with several U.S. allies.  

Generic drugs and biosimilars are excluded from the tariffs for now, reflecting affordability and supply considerations. Federal agencies are directed to monitor the impact and recommend further action if needed.